Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

The Role of Life Sciences Consulting in California's Medical Device Innovation

Sep 13, 2025

Introduction to Life Sciences Consulting

In the bustling landscape of California's medical device sector, life sciences consulting plays a pivotal role in fostering innovation. These consulting firms provide invaluable expertise and resources that help companies navigate the complex regulatory, scientific, and market environments. Their contribution is crucial in ensuring that new medical devices not only meet stringent safety standards but also reach the market efficiently.

life sciences consulting

Why California?

California is a hotspot for medical device innovation due to its robust ecosystem comprising top-tier research institutions, a thriving startup scene, and a strong presence of established companies. This dynamic environment creates an ideal breeding ground for innovation, attracting life sciences consultants who offer specialized services to drive progress. The combination of cutting-edge research and business acumen found in California is unmatched.

The state's supportive regulatory framework further enhances its appeal. California's policies encourage innovation while ensuring public safety, and life sciences consultants are adept at guiding companies through this regulatory maze. By working closely with regulatory bodies, consultants help ensure that innovative medical devices comply with all necessary standards.

The Services Offered by Life Sciences Consultants

Life sciences consulting firms offer a wide array of services tailored to the needs of medical device companies. These services include:

  • Regulatory Strategy: Developing strategies to meet FDA requirements and other regulatory standards.
  • Clinical Trial Management: Designing and managing clinical trials to validate device efficacy and safety.
  • Market Analysis: Conducting comprehensive market research to identify opportunities and challenges.
  • Product Development: Assisting in the design and development of innovative medical devices.
medical device consulting

The Impact on Innovation

The services provided by life sciences consultants significantly impact the pace and success of innovation within the medical device industry. By offering expert guidance, these consultants enable companies to focus on their core competencies, such as research and development, while ensuring adherence to regulatory requirements. This approach not only accelerates time-to-market but also reduces the risk of costly compliance issues.

Moreover, consultants often facilitate collaborations between different stakeholders in the industry, including researchers, manufacturers, and investors. These collaborations are essential for fostering innovation and driving the development of groundbreaking medical devices that can transform patient care.

Case Studies: Success Stories

Several success stories highlight the critical role of life sciences consulting in California's medical device sector. For instance, a small startup was able to secure FDA approval for its innovative diagnostic tool by partnering with a consulting firm that provided strategic regulatory guidance and conducted thorough market research. Another company successfully launched a novel therapeutic device thanks to expert clinical trial management offered by their consulting partner.

innovation success

The Future of Life Sciences Consulting

As technology continues to advance, the demand for specialized life sciences consulting services is expected to grow. Emerging fields such as digital health, personalized medicine, and artificial intelligence offer new opportunities for innovation within the medical device industry. Life sciences consultants will play a vital role in helping companies navigate these frontiers by offering expertise in areas such as data analytics, cybersecurity, and ethical compliance.

In conclusion, life sciences consulting is a cornerstone of California's medical device innovation ecosystem. By providing essential services and fostering collaboration, these consultants drive progress and ensure that groundbreaking medical devices reach the patients who need them most.